Journal Information
Vol. 36. Issue. 6.November - December 2016
Pages 583-722
Download PDF
More article options
Vol. 36. Issue. 6.November - December 2016
Pages 583-722
Letter to the Editor
Open Access
Gaucher disease and Lupus: A rare association?
Gaucher y lupus: ¿una rara asociación?
Teresa Jerónimoa,
Corresponding author

Corresponding author.
, Ana Cabritaa, Ana Pimentela, Joana Vidinhaa, André Fragosoa, Viriato Santosa, Idalécio Bernardoa, Helena Vianab, Fernanda Carvalhob, Helena Britoc, Mário Lázaroc, Pedro Leão Nevesa
a Nephrology Department, Centro Hospitalar do Algarve – Faro Unit, Rua Leão Penedo, 8000-386 Faro, Portugal
b Renal Pathology Laboratory, Nephrology Department, Hospital Curry Cabral, Rua da Beneficência, n.° 8, 1069-166 Lisboa, Portugal
c Internal Medicine Department, Centro Hospitalar do Algarve – Faro Unit, Rua Leão Penedo, 8000-386 Faro, Portugal
Article information
Full Text
Download PDF
Tables (1)
Table 1. Laboratory parameters.
Full Text
Dear Editor,

Gaucher disease (GD), is an autosomal recessive lysosomal storage disease that is due to mutations in the glucocerebrosidase (GC) gene, with a prevalence of 1/57,000 to 1/75,000 births worldwide1 and significantly more common among the Ashkenazi Jewish heritage.2 GD is categorized into three clinical types4 and the clinical manifestations result from the accumulation of the lipid-laden macrophages in the spleen, liver, bone, bone marrow,3 leading to impairment of central nervous system in the most severe cases.4

Although several reports are available related to the risk of GD patients developing other diseases like Parkinson's disease5 and increased rates of malignancies, particularly hematologic,6 systemic lupus erythematous (SLE) has not been described in association with GD.

We report a case of a 32-year-old Caucasian woman diagnosed with GD type 1 at 17 years-old. She had a grandmother with GD, an uncle with SLE and a cousin with rheumatoid arthritis. There is no known Jewish heritage in her family. She was medicated with velaglucerase.

With 30 years old, the patient developed malar-rash and chest eczema, associated with sun exposure. One year after she noticed worsening asthenia, anorexia, nausea, hair loss, myalgias, bilateral gonalgia, oral ulcers, Raynaud syndrome and arterial hypertension (TA 140/90mmHg). The patient was referred to the nephrology unit with peripheral edema and the laboratory investigation showed parameters of ferropenic anemia (without signs of hemolysis), leukopenia, thrombocytopenia, elevated seric creatinine, hypoalbuminemia, active urinary sediment and nephrotic-range proteinuria observed in the 24h urine sample (Table 1). The immune assays revealed positive antinuclear antibodies (ANA) and anti-Sjögren's-syndrome-related antigen A, elevated immunoglobulin (Ig) G (20.7g/L) and IgA (4.64g/L), circulating immunocomplexes (>100μgEq/mL) and low serum complement (C3 0.16g/L, C4 0.021g/L, C1q 0.208g/L). The complementary immunologic and serologic study was negative. Renal and abdominal ultrasounds showed normal sized kidneys, increased cortical echogenicity with maintained differentiation and mild/moderate homogeneous hepatosplenomegaly. Echocardiogram revealed thickened pericardium and nuclear magnetic resonance of the inferior members showed bone alterations and moderate intra-articular left knee and mild right knee effusion.

Table 1.

Laboratory parameters.

  Admission  Discharge  6 months  12 months 
Hb (g/dL)  9.1  8.9  13.6  13.2 
Leukcocytes (×109/L)  2900  7400  5900  4500 
Platelets (×109/L)  87,000  168,000  237,000  367,000 
Creatinine (mg/dL)  1.382.1  1.5  0.73  0.7 
Albumin (g/dL)  2.1  3.1  4.1  4.2 
Urinary sediment – erythrocyts (μL−1225 (15% dysmorphic)  –  8 (8% dysmorphic)  10 (4% dysmorphic) 
Urinary proteins (mg/24h)  7600  4500  341  283 
ANA  Positive  –  Positive  Positive 
Anti-SSA (UA/mL)  786  –  Positive  Positive 
Anti-dsDNA  Negative  –  182  83 
C3 (g/L)  0.16  0.42  0.78  0.90 
C4 (g/L)  0.021  0.052  0.085  0.074 

ANA, antinuclear antibodies; anti-SSA, anti-Sjögren's-syndrome-related antigen A; anti-dsDNA, anti-double stranded DNA; C3, complement 3; C4, complement 4.

Kidney biopsy established the diagnosis of class IV-G lupus nephritis (LN) and the treatment according to KDIGO (Kidney Disease: Improving Global Outcomes) guideline7 was started. Hydroxychloroquine was redrawn due to gastric intolerance. She was discharged 1 month after admission with serum creatinine 1.5mg/dL, proteinuria 4500mg observed in the 24h urine sample (mg/24h), complement levels arose and albuminemia was at the normal range (Table 1). Six months after discharge the patient is clinically stable, with normal renal function, proteinuria of 341mg/24h and an amelioration of complement. Anti-double stranded DNA was positive for the first time 6 months after discharge (182U/mL) and decreased to 83U/mL in the following 6 months (Table 1).

We describe this case of a patient with GD and SLE simultaneously with the purpose of highlighting a possible immunologic proximity between these two diseases. Although the presence of renal pathology in GD is rather rare, it consists of varying degrees of proteinuria with or without renal insufficiency and it has been described in some patients associated with the accumulation of GC in form of Gaucher bodies in glomerular, mesangial, endothelial and interstitial cells of the kidney.8 It has been suggested that progressive accumulation of GC may trigger macrophage activation leading to chronic stimulation of the immune system.9 Increasing clinical evidence suggests that the pathophysiology of classic GD is more complex and involves system-wide dysfunction of cell types other than macrophages.10 Therefore, the immunological disturbances that occur in GD may function as a trigger to the development of SLE, bringing up the already existing doubt that the defects in lipid metabolism could contribute to the development of autoimmunity. In this particular case, clinical and laboratory results could led to a diagnosis of SLE: presence of 4 or more criteria, at least one clinical and one laboratorial Systemic Lupus International Collaborating Clinic (SLICC) criteria. However, and besides the clinical manifestations of malar rash associated with sun exposure, other like arthralgia, pancytopenia and hepatosplenomegaly were easily confounded with GD manifestations and the SLE diagnosis was not achieved until the renal manifestations occurred. The kidney biopsy revealing LN with positive ANA was preponderant to the diagnosis of SLE, according to SLICC criteria. Determining the class of LN was also important to guide the treatment by the histologic subtype, as the clinical presentation may not accurately reflect the severity of the histologic findings, and there was a positive clinical and laboratorial response.

However, the relationship between GD and SLE is not yet established. The involvement of immune cells has been implicated, but the underlying molecular defect is poorly understood. Further studies are necessary to highlight the possible immunologic proximity between these two rare conditions.


Informed consent to publish individual data was obtained from the patient.

Conflict of interest

The authors declare no conflict of interest.

P.J. Meikle, J.J. Hopwood, A.E. Clague, W.F. Carey.
Prevalence of lysosomal storage disorders.
JAMA, 281 (1999), pp. 249
E. Beutler, G.A. Grabowski.
Glucosylceramide lipidosis – Gaucher disease.
The metabolic and molecular bases of inherited diseases, 8th ed., pp. 3635-3668
T.M. Cox.
Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses.
J Inherit Metab Dis, 24 (2001), pp. 106
G.A. Grabowski.
Gaucher disease, enzymology, genetics, and treatment.
Adv Hum Genet, 21 (1993), pp. 377-441
J. Aharon-Peretz, H. Rosenbaum, R. Gershoni-Baruch.
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.
N Engl J Med, 351 (2004), pp. 1972-1977
S.M. Lo, P. Stein, S. Mullaly, M. Bar, D. Jain, G.M. Pastores, et al.
Expanding spectrum of the association between type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types – correlation with genotype and phenotype.
Am J Hematol, 85 (2010), pp. 340
KDIGO clinical practice guideline for glomerulonephritis.
Kidney Int Suppl, 2 (2012), pp. 221-232
E. Rosenmann, A. Aviram.
Glomerular involvement in storage diseases.
J Pathol, 111 (1973), pp. 61-64
Y. Shoenfield, L.A. Gallant, M. Shaklai, E. Livni, M. Djaldetti, J. Pinkhas.
Gaucher's disease: a disease with chronic stimulation of the immune system.
Arch Pathol Lab Med, 106 (1982), pp. 388-391
P.K. Mistry, J. Liu, M. Yang, T. Nottoli, J. McGrath, D. Jain, et al.
Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage.
Proc Natl Acad Sci U S A, 107 (2010), pp. 19473-19478
Copyright © 2016. Sociedad Española de Nefrología
Nefrología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?